Literature DB >> 28636951

Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.

Yi Zheng1, Gye Won Han2, Ruben Abagyan1, Beili Wu3, Raymond C Stevens4, Vadim Cherezov2, Irina Kufareva5, Tracy M Handel6.   

Abstract

CCR5 is the primary chemokine receptor utilized by HIV to infect leukocytes, whereas CCR5 ligands inhibit infection by blocking CCR5 engagement with HIV gp120. To guide the design of improved therapeutics, we solved the structure of CCR5 in complex with chemokine antagonist [5P7]CCL5. Several structural features appeared to contribute to the anti-HIV potency of [5P7]CCL5, including the distinct chemokine orientation relative to the receptor, the near-complete occupancy of the receptor binding pocket, the dense network of intermolecular hydrogen bonds, and the similarity of binding determinants with the FDA-approved HIV inhibitor Maraviroc. Molecular modeling indicated that HIV gp120 mimicked the chemokine interaction with CCR5, providing an explanation for the ability of CCR5 to recognize diverse ligands and gp120 variants. Our findings reveal that structural plasticity facilitates receptor-chemokine specificity and enables exploitation by HIV, and provide insight into the design of small molecule and protein inhibitors for HIV and other CCR5-mediated diseases.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CCL5/RANTES; CCR5-gp120 interaction; Chemokine antagonist; G protein-coupled receptor (GPCR); HIV entry inhibitor; V3 loop; maraviroc; membrane protein structure; two-site model; viral mimicry

Mesh:

Substances:

Year:  2017        PMID: 28636951      PMCID: PMC5572563          DOI: 10.1016/j.immuni.2017.05.002

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  67 in total

1.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

2.  A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands.

Authors:  David C Swinney; Paul Beavis; Kai-Ting Chuang; Yue Zheng; Ina Lee; Peter Gee; Jerome Deval; David M Rotstein; Marianna Dioszegi; Palani Ravendran; Jun Zhang; Surya Sankuratri; Rama Kondru; Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 3.  CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.

Authors:  Guillaume Martin-Blondel; David Brassat; Jan Bauer; Hans Lassmann; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

4.  Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5.

Authors:  Spencer E Hall; Allen Mao; Vicky Nicolaidou; Mattea Finelli; Emma L Wise; Belinda Nedjai; Julie Kanjanapangka; Paymann Harirchian; Deborah Chen; Victor Selchau; Sofia Ribeiro; Sabine Schyler; James E Pease; Richard Horuk; Nagarajan Vaidehi
Journal:  Mol Pharmacol       Date:  2009-03-18       Impact factor: 4.436

5.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

6.  Microscale fluorescent thermal stability assay for membrane proteins.

Authors:  Alexander I Alexandrov; Mauro Mileni; Ellen Y T Chien; Michael A Hanson; Raymond C Stevens
Journal:  Structure       Date:  2008-03       Impact factor: 5.006

7.  Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices.

Authors:  Melanie P Wescott; Irina Kufareva; Cheryl Paes; Jason R Goodman; Yana Thaker; Bridget A Puffer; Eli Berdougo; Joseph B Rucker; Tracy M Handel; Benjamin J Doranz
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-19       Impact factor: 11.205

8.  Structural and molecular interactions of CCR5 inhibitors with CCR5.

Authors:  Kenji Maeda; Debananda Das; Hiromi Ogata-Aoki; Hirotomo Nakata; Toshikazu Miyakawa; Yasushi Tojo; Rachael Norman; Yoshikazu Takaoka; Jianping Ding; Gail F Arnold; Eddy Arnold; Hiroaki Mitsuya
Journal:  J Biol Chem       Date:  2006-02-13       Impact factor: 5.157

Review 9.  Biased and g protein-independent signaling of chemokine receptors.

Authors:  Anne Steen; Olav Larsen; Stefanie Thiele; Mette M Rosenkilde
Journal:  Front Immunol       Date:  2014-06-23       Impact factor: 7.561

10.  A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris.

Authors:  Fabrice Cerini; Hubert Gaertner; Knut Madden; Ilya Tolstorukov; Scott Brown; Bram Laukens; Nico Callewaert; Jay C Harner; Anna M Oommen; John T Harms; Anthony R Sump; Robert C Sealock; Dustin J Peterson; Scott K Johnson; Stephan B Abramson; Michael Meagher; Robin Offord; Oliver Hartley
Journal:  Protein Expr Purif       Date:  2015-10-24       Impact factor: 1.650

View more
  65 in total

1.  High-Affinity Binding of Chemokine Analogs that Display Ligand Bias at the HIV-1 Coreceptor CCR5.

Authors:  Carlos A Rico; Yamina A Berchiche; Mizuho Horioka; Jennifer C Peeler; Emily Lorenzen; He Tian; Manija A Kazmi; Alexandre Fürstenberg; Hubert Gaertner; Oliver Hartley; Thomas P Sakmar; Thomas Huber
Journal:  Biophys J       Date:  2019-08-02       Impact factor: 4.033

2.  Functional anatomy of the full-length CXCR4-CXCL12 complex systematically dissected by quantitative model-guided mutagenesis.

Authors:  Bryan S Stephens; Tony Ngo; Irina Kufareva; Tracy M Handel
Journal:  Sci Signal       Date:  2020-07-14       Impact factor: 8.192

3.  Comparative modeling and docking of chemokine-receptor interactions with Rosetta.

Authors:  Michael J Wedemeyer; Benjamin K Mueller; Brian J Bender; Jens Meiler; Brian F Volkman
Journal:  Biochem Biophys Res Commun       Date:  2020-01-07       Impact factor: 3.575

4.  Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.

Authors:  Martyna Szpakowska; Amanda M Nevins; Max Meyrath; David Rhainds; Thomas D'huys; François Guité-Vinet; Nadine Dupuis; Pierre-Arnaud Gauthier; Manuel Counson; Andrew Kleist; Geneviève St-Onge; Julien Hanson; Dominique Schols; Brian F Volkman; Nikolaus Heveker; Andy Chevigné
Journal:  Br J Pharmacol       Date:  2018-03-23       Impact factor: 8.739

5.  A benchmark study of loop modeling methods applied to G protein-coupled receptors.

Authors:  Lee H Wink; Daniel L Baker; Judith A Cole; Abby L Parrill
Journal:  J Comput Aided Mol Des       Date:  2019-05-23       Impact factor: 3.686

6.  The chemokine X-factor: Structure-function analysis of the CXC motif at CXCR4 and ACKR3.

Authors:  Michael J Wedemeyer; Sarah A Mahn; Anthony E Getschman; Kyler S Crawford; Francis C Peterson; Adriano Marchese; John D McCorvy; Brian F Volkman
Journal:  J Biol Chem       Date:  2020-08-11       Impact factor: 5.157

7.  Structure-function guided modeling of chemokine-GPCR specificity for the chemokine XCL1 and its receptor XCR1.

Authors:  Jamie C Fox; Monica A Thomas; Acacia F Dishman; Olav Larsen; Takashi Nakayama; Osamu Yoshie; Mette Marie Rosenkilde; Brian F Volkman
Journal:  Sci Signal       Date:  2019-09-03       Impact factor: 8.192

Review 8.  Cytokines and chemokines involved in the defense reaction against HIV-1 and hepatitis B virus: isn't it time to use a standardized nomenclature of the involved mediators?

Authors:  Lutz G Gürtler
Journal:  Virus Genes       Date:  2019-12-17       Impact factor: 2.332

Review 9.  Harnessing Ion-Binding Sites for GPCR Pharmacology.

Authors:  Barbara Zarzycka; Saheem A Zaidi; Bryan L Roth; Vsevolod Katritch
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

Review 10.  Advances in therapeutic peptides targeting G protein-coupled receptors.

Authors:  Anthony P Davenport; Conor C G Scully; Chris de Graaf; Alastair J H Brown; Janet J Maguire
Journal:  Nat Rev Drug Discov       Date:  2020-03-19       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.